Predictive Oncology Inc. POAI Archives - Page 4 of 19

MondayMar 08, 2021 12:24 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Development of Newly Designed System for Direct-to-Drain Fluid Waste Management

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its Skyline Medical Division is renewing the development of a new Generation 3 STREAMWAY(R) System for direct-to-drain fluid waste management. According to the update the new device will see no change to its intended use and will not require a separate 501(k) submission with the Food and Drug Administration. In addition, the new design will include key changes to the product that will be smaller, lighter and easier to install with the goal of improving operator reliability, reducing…

FridayMar 05, 2021 12:20 pm

Predictive Oncology Inc. (NASDAQ: POAI) Announces Fundraising Agreements to Raise Estimated $25M

POAI completes two separate fundraising initiatives: private placement, direct offering. Two fundraising campaigns expected to result in $17.6 million, $7.4 million respectively. Predictive Oncology plans to use funds to pay off debt as well as for working capital, general corporate purposes. Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced two funding initiatives that together total an estimated $25 million. The company has entered into securities purchase agreements with institutional and accredited investors (https://ibn.fm/WH4nw) to raise approximately $17.6 million and is involved in a direct offering that is expected…

ThursdayMar 04, 2021 2:25 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leveraging AI, Proprietary Database to Improve Outcomes for Patients of Today and Tomorrow

Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company focused on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has been a forerunner in the field, helping oncologists individualize cancer treatment through its Helomics division. A recent article discussing this reads, “Predictive Oncology is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is…

FridayFeb 26, 2021 2:05 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Looks to AI to Improve Clinical Decision Making for Ovarian Cancer Patients

Predictive Oncology (NASDAQ: POAI), through its wholly owned subsidiary, Helomics, has sought to end the alarming statistics surrounding ovarian cancer. According to figures provided by the American Cancer Society and quoted by an article discussing POAI’s motivations and operations, “an estimated 21,750 women received a new diagnosis of ovarian cancer this year (2020), and almost 14,000 women will die from the disease. Those numbers make ovarian cancer the fifth-leading cause of cancer deaths in women.” In a bid to change this reality, Predictive Oncology, a company that focuses on using data and artificial intelligence to develop personalized cancer therapies, has…

FridayFeb 26, 2021 1:36 pm

Predictive Oncology Inc. (NASDAQ: POAI) Receives ‘Buy’ Rating from Litchfield Hills Research in First Analyst Coverage Report

Calling POAI undervalued, Litchfield initiates coverage of Predictive Oncology with Buy rating, $3 price target The drug industry is changing as tools and technology to tailor drugs emerge, regulatory bodies focus on patients’ experiences, perspectives, needs Litchfield report notes several POAI strengths under “Investment Thesis” section A growing number of companies and health providers alike are paying attention to what the FDA is calling patient-focused drug development (“PFDD”), a systematic approach to help ensure that patients’ experiences, perspectives, needs and priorities are captured and meaningfully incorporated into drug development and evaluation. In that growing market, Predictive Oncology (NASDAQ: POAI), a…

WednesdayFeb 24, 2021 1:18 pm

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiaries Ink Significant Contract, Announce Sale of Media to Top Medical Centers

POAI subsidiary inks contract with significant pharmaceutical company TumorGenesis announces sale of media to research medical centers in New York City, Boston Potential market for 3D cancer cell culture media expected to reach $3.2 billion sales worldwide by 2027 Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that one of its wholly owned subsidiaries, Soluble Biotech, recently inked another contract with a large pharmaceutical company (https://ibn.fm/OpaJb). POAI also announced that TumorGenesis, one of its wholly owned subsidiaries, has sold media to two top research medical centers (https://ibn.fm/uXorQ). Soluble Biotech’s contract will…

WednesdayFeb 24, 2021 9:32 am

QualityStocksNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes $17.6M Private Placement; Reaches Key Milestones in Developing AI-Driven Model of Ovarian Cancer

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery closed on its previously announced private placement of common stock and warrants. Priced at-the-market under Nasdaq rules, the 9,043,766 shares of common stocks and warrants were issued and sold by the company in order to purchase no more than 4,521,883 shares of common stock in the private placement. The common stock and associated warrants were issued for $1.95 each, with the warrants having an exercise price of $2 per share. The shares are exercisable immediately; however, they do have a five and…

ThursdayFeb 18, 2021 11:57 am

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces $17.6M Private Placement

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its entry into securities purchase agreements with certain institutional and accredited investors to raise approximately $17.6 million through the issuance of an aggregate of 9,043,766 shares of its common stock and warrants to purchase up to an aggregate of 4,521,883 shares of common stock, at a purchase price of $1.95 per share of common stock and associated warrant. The private placement is priced at-the-market under Nasdaq rules. Subject to the satisfaction of customary conditions, the closing of the private…

WednesdayFeb 17, 2021 10:47 am

QualityStocksNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes on $7.4M Registered Direct Offering, Announces Breakthrough Discoveries

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it had closed on its previously announced registered direct offering. The offering, comprised of 4,222,288 shares of POAI common stock sold at $1.75 per share, totaled $7.4 million in gross proceeds for the company, before expenses were deducted. The shares were priced at-the-market under Nasdaq rules. The announcement also noted that the company issued a concurrent private placement to the same investors; that placement comprised of unregistered warrants up 2,111,144 shares of common stock, priced at $2 per share.…

ThursdayFeb 11, 2021 10:11 am

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces $7.4M Registered Direct Offering

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced its entry into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of approximately 4,222,288 shares of its common stock. The company expects gross proceeds of approximately $7.4 million, with each of the shares sold a purchase price of $1.75, in the registered direct offering priced at-the-market under Nasdaq rules. Predictive Oncology has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of approximately 2,111,114 shares…

Site Search

Company Search

Tag: Predictive Oncology Inc. POAI